STAAR Surgical (STAA) Q4 2025 earnings review
China Rebound Lifts Revenue, But Alcon Fallout and Missing Guidance Cloud the Outlook
Q4 revenue rose 18% YoY to $57.8M, driven by a partial China recovery ($17.5M vs $7.9M a year ago). Adjusted EBITDA reached breakeven at $(0.2)M, a dramatic improvement from the $(20.8)M loss in Q4 2024, thanks to a 8% cut in adjusted operating expenses. However, the quarter disappointed on two fronts: China sub-distributors returned inventory due to Alcon merger uncertainty, and ex-China sales declined 2% as EMEA distributors also pulled back. For FY2025, revenue fell 24% to $239M with a net loss of $(80)M. Management is not providing FY2026 guidance but is 'targeting profitability,' citing stabilized China inventory, cost discipline, and the EVO+ launch.
🐂 Bull Case
Distributor inventory is now at or below the six-month contractual level, monitored weekly with new processes. In-market demand recovered to mid-single-digit growth in FY2025 after a double-digit decline in FY2024, with Q4 showing acceleration. STAAR is positioned for clean sell-in in 2026.
Adjusted OpEx fell 9.4% to $228M, beating the $225M target. Adjusted EBITDA swung from $(20.8)M to breakeven in Q4 on just $57.8M revenue. As revenue recovers toward historical levels ($300M+), high gross margins (~76%) should translate into significant operating leverage.
The first new lens in China in over a decade has launched with encouraging early demand and a premium ASP. Manufactured in Switzerland (tariff-free), EVO+ gives STAAR both pricing power and supply chain resilience. Management reports customers 'see the difference and patients are paying for the difference.'
🐻 Bear Case
Guidance was withdrawn in Q1 2025 and still not reinstated. The refusal to provide even a revenue range for FY2026 — after a full year of 'transition' — suggests management cannot confidently forecast China demand or the pace of ex-China recovery.
The CEO search is underway via an external firm. Two interim co-CEOs are managing through the most important inflection point in the company's recent history. Leadership uncertainty could slow strategic decisions and create organizational distraction.
Ex-China growth decelerated from +9%/+10%/+8% in Q1-Q3 to -2.1% in Q4. EMEA fell 20% due to distributor disruption. While management blames Alcon uncertainty, the trend needs to reverse quickly or the ex-China growth story weakens.
⚖️ Verdict: ⚪
Neutral. The recovery setup is genuinely better — inventory is clean, costs are controlled, and EVO+ is a real catalyst. But with no guidance, interim leadership, and a Q4 that missed on both China and ex-China due to distributor disruption, this remains a show-me story. FY2026 H1 results will determine whether the turnaround is real.
Key Themes
China Inventory Normalized — Clean Starting Point for 2026
The most important operational achievement of FY2025: China distributor inventory has been drawn down to contractual levels (approximately six months of supply) after an estimated $80-85M reduction during the year. In-market EVO ICL demand recovered to mid-single-digit growth in FY2025 after a double-digit decline in FY2024, with Q4 showing acceleration. STAAR now monitors inventory weekly through improved data processes. However, Q4 China net sales of $17.5M came in below expectations because certain sub-distributors and customers returned inventory to distributors amid Alcon acquisition uncertainty, adding one more quarter of noise before the clean start.
Cost Restructuring Beat Target — Adjusted EBITDA Near Breakeven
Adjusted operating expenses (excluding merger and restructuring costs) fell to $228M in FY2025, a 9.4% reduction from $252M in FY2024, beating the $225M annualized run-rate target communicated in Q1 2025. S&M expenses declined 12.4% and R&D fell 11.6%. The result: Q4 adjusted EBITDA reached $(0.2)M — essentially breakeven — versus a $(20.8)M loss a year ago. However, stock-based compensation rose 12.4% to $30.6M, meaning the GAAP cost picture is less improved. Management commits to maintaining the ~$225M OpEx run rate in FY2026.
EVO+ Launched in China with Premium ASP
STAAR's first new lens in China in over a decade is now commercially available, manufactured at the Swiss facility (not subject to U.S.-China tariffs). Early demand is 'encouraging,' with customers seeing the product differentiation and patients paying a premium price. Management declined to disclose the specific ASP uplift, calling it a competitive advantage. EVO+ is expected to drive both volume growth and margin expansion over time as Swiss production scales. The combination of premium pricing and tariff-free supply chain makes EVO+ the centerpiece of the 2026 China growth story.
Swiss Manufacturing Now Producing Commercial Product
The Nidau, Switzerland facility has moved from validation to commercial production, focused on EVO+ for China. Swiss-manufactured product eliminates exposure to U.S.-China tariffs that previously required emergency consignment inventory deployments. The facility provides both tariff mitigation and long-term capacity for growth (targeting 300K+ lenses/year by end of 2026, with potential for 800K+). However, higher Swiss manufacturing costs will create a gross margin headwind in FY2026 as this inventory is sold.
Alcon Merger Disruption Depressed Q4 Across All Regions
The terminated Alcon acquisition created widespread channel disruption in Q4. In China, sub-distributors and customers returned inventory to distributors due to uncertainty about their future under Alcon ownership. In EMEA, distributor dynamics drove a 20% revenue decline including a distributor transition in the Middle East. Even distributors in other regions reduced purchases. While this disruption is now behind the company, it means Q4 results cannot be used as a baseline for 2026 and the cumulative revenue loss may take quarters to recover.
Ex-China Growth Stalled — Deceleration Needs Monitoring
Ex-China revenue growth decelerated sharply across FY2025: from +9% in Q1, to +10% in Q2, +8% in Q3, then -2.1% in Q4. For the full year, ex-China grew only 6.6% to $161.7M — missing the prior guidance range of $165-175M. Management attributes Q4 weakness entirely to Alcon disruption, and the Americas remained strong at +18% in Q4. But the overall deceleration means ex-China revenue has plateaued around $40M per quarter. If this doesn't re-accelerate in 2026, the 'growth outside China' narrative weakens.
Leadership Transition at a Critical Inflection Point
Warren Foust and Deborah Andrews assumed interim co-CEO roles on February 1, 2026 after the prior CEO's departure. A global search for a permanent CEO is underway through Egon Zehnder, including internal and external candidates. While both leaders bring deep operational knowledge, interim leadership during a critical recovery year creates execution risk. Strategic decisions on market investment, innovation pipeline acceleration, and China go-to-market may be delayed until a permanent CEO is installed.
Inventory Build and Product Expiration Risk
Company inventory rose 28% to $55.5M even as revenue fell 24%. Some buildup reflects the Swiss manufacturing ramp and consignment strategy, but $5.3M in inventory provisions (up from $2.8M in FY2024) signals increasing product expiration. Management flagged 'increased inventory reserves from expiring product' as a FY2026 gross margin headwind. This raises questions about demand planning accuracy and whether excess inventory from the 2024-2025 disruption period will continue to weigh on profitability.
Competitive Landscape: New Entrants in China
Eyebright (iBright) continues to build presence in China with a phakic IOL competitor. Management remains confident in STAAR's competitive moat — 30+ years of Collamer polymer technology, toric lenses, and 4M+ implants — noting that competitors offer acrylic-based lenses with 'a more rigid structure.' Historically, most phakic IOL competitors have failed to sustain market presence. However, Warren Foust acknowledged the category growth is 'a little flattering,' meaning competitors are benefiting from the same LASIK-to-lens shift. The lack of a toric offering from competitors and the EVO+ premium tier provide near-term protection, but monitoring is required as the market grows.
Lens-Based Refractive Surgery Continues Taking Share from LASIK
Across nearly all markets, surgeons are moving away from corneal tissue-removing LASIK toward reversible, lens-based procedures. In the U.S., STAAR grew double digits in FY2025 while the laser vision correction market continued to decline. The expanded age indication (21-60 years) adds an estimated 8 million potential U.S. candidates. In Brazil, label expansion to -0.5 diopters (from -6.0) opens the lower myopia segment. The LASIK-to-lens shift is a durable secular tailwind, though STAAR acknowledges it has not yet made sufficient progress penetrating lower diopter patients, which comprise the majority of the refractive market.
Other KPIs
Recovered strongly from 64.7% in Q4 2024, which was depressed by $3.9M in cost of sales for the deferred December 2024 China shipment. Q4 2025 benefited from cost reductions and Swiss manufacturing ramp-up, partially offset by higher inventory provisions. The FY2025 gross margin of 76.2% was flat versus 76.3% in FY2024, masking wild quarterly swings (65.8% in Q1, 82.2% in Q3 when $25.9M deferred revenue was recognized at 100% margin). Management warns FY2026 gross margin will be 'slightly lower' than FY2025 due to higher-cost Swiss manufacturing inventory and expiring product reserves.
Down $43M from $230.5M a year ago despite no debt. FY2025 operating cash flow was negative $(34.2)M (vs positive $15.7M in FY2024), and the company spent $5.8M on CapEx and $15.8M on cloud-based software (Oracle ERP implementation). Partly offsetting: $127.5M in proceeds from investment maturities and $3.5M from stock option exercises. The $187.5M closing balance exceeded prior guidance of $150-175M, demonstrating better-than-feared cash management. Management expects a modest dip in early FY2026 before resuming cash generation in H2 and ending 2026 above $187.5M.
Down 36% from $77.9M at year-end FY2024. The decline reflects collections on the $27.5M deferred December 2024 China shipment (fully recognized by Q3 2025) and reduced China shipment volumes throughout 2025. The AR reduction is a positive working capital development and reduces credit risk from the China distribution channel. However, inventory rose 28% to $55.5M, partially offsetting the AR improvement.
Guidance
Management declined to provide revenue guidance, citing uncertainty. Qualitatively, they expect FY2026 revenue to be 'significantly' higher than FY2025's $239M. Warren Foust cautioned he does not expect 20-25% growth, though 'that is definitely what we're working to.' Q2 and Q3 are expected to remain seasonally strong. At a conservatively estimated 10-15% growth, FY2026 revenue would be $263-275M — still well below FY2024's $314M or FY2023's $322M.
The company is targeting a return to profitability in FY2026, driven by revenue growth on a right-sized cost base. FY2025 adjusted EBITDA was $(6.6)M. With $225M in OpEx and ~75% gross margins, STAAR needs roughly $300M in revenue to reach EBITDA breakeven (before SBC). Achieving profitability at the $263-275M revenue range implied by qualitative guidance would require meaningful gross margin improvement or further cost cuts — making this target ambitious.
Decelerating. Management flagged two headwinds: higher cost of inventory from Swiss manufacturing being sold in FY2026, and increased inventory reserves from expiring product. Offsetting tailwinds include EVO+ premium ASPs, improved manufacturing yields, and efficiencies, though these are expected to benefit FY2027 more than FY2026. A slight decline to ~74-75% seems likely.
Stable. The $225M adjusted run rate achieved in FY2025 will carry forward. This compares to $252M in FY2024 and implies continued discipline. Key investments include completion of the Oracle ERP implementation (expected early H2 2026) and the Stella online sizing/ordering platform. Merger and restructuring costs ($45.8M in FY2025) should largely drop off, removing a major source of GAAP expense inflation.
Ex-China ICL sales came in at $161.7M vs guidance of $165-175M (miss). China H2 sales were approximately $72M vs guidance of $75-125M (missed low end). However, adjusted EBITDA of $(6.6)M significantly beat the guided range of $(15)M to $(50)M, and the cash balance of $187.5M beat $150-175M. The message: management controlled what it could (costs, cash) but could not control China demand timing or Alcon disruption.
Key Questions
FY2026 Revenue Visibility
You expect 'significant' sales growth but won't provide a range. What specific milestones — China monthly sell-through, distributor ordering patterns, ex-China pipeline — would give you enough confidence to reinstate guidance? And at what point in FY2026 should investors expect formal targets?
CEO Search Timeline and Strategic Continuity
The Egon Zehnder search includes internal and external candidates. What is the expected timeline? If a new CEO brings a different strategic vision — for example, prioritizing the U.S. over China or pursuing M&A — how protected are the current 'growth, profit, and innovation' priorities?
EVO+ Economics and Swiss Manufacturing Ramp
You reported early EVO+ demand is encouraging with a premium ASP. What is the current Swiss facility production rate versus target? What percentage of China demand can Swiss production serve today, and when will you fully transition away from U.S.-manufactured lenses for China?
Inventory Build Explanation
Inventory rose 28% to $55.5M while revenue fell 24%. How much of this is Swiss manufacturing ramp versus unsold product? What is the shelf life of EVO/EVO+ lenses, and what level of inventory provisions should we expect in FY2026?